(1-Benzylazetidin-3-yl)methanamine dihydrochloride is primarily utilized in pharmaceutical research and development, particularly in the synthesis of novel compounds targeting central nervous system disorders. Its structure is often explored for its potential as a building block in the creation of ligands for neurotransmitter receptors, such as those involved in dopamine or serotonin pathways. This compound may also be investigated for its role in modulating enzyme activity or as a precursor in the development of drugs aimed at treating neurological conditions like Parkinson's disease, depression, or anxiety. Additionally, its application extends to medicinal chemistry studies, where it serves as a key intermediate in optimizing drug candidates for improved efficacy and selectivity.